Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Small pools, big ideas: How the rare disease community is reimagining clinical trials
(12h)
RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design
(15h)
'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
(18h)
Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx
(18h)
Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
(18h)
Aligos sells China rights to HPV drug to hepatology player Amoytop in $445M deal
(19h)
Qiagen launches latest diagnostic for bloodstream infections
(20h)
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
(1d)
FDA advisory committee set to weigh taking action on certain unapproved peptides
(1d)
How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients
(1d)
BioPharma Dive
Kailera nets $625M in one of biotech’s biggest-ever IPOs
(8h)
Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director
(10h)
FDA moves toward easing restrictions on certain peptides
(17h)
Lilly’s new obesity pill passes heart safety test in diabetes
(17h)
Replimune cuts staff; MeiraGTx reacquires eye gene therapy
(17h)
Roche to start new Elevidys study following setback in Europe
(18h)
Bain-backed biotech Beeline debuts with immune drugs from Bristol Myers
(1d)
Terremoto raises $108M to pursue development of drugs targeting AKT
(1d)
FDA asks Lilly to evaluate obesity pill’s liver risk
(1d)
Obsidian, Galera to advance cell therapy following reverse merger
(1d)
Endpoints News
RFK Jr. defends FDA, Makary following Republican questions
(13h)
OpenAI launches biopharma-focused AI model to compete with Anthropic
(13h)
Cochrane review dismissing amyloid drugs draws immediate backlash
(16h)
Roche to start a new Phase 3 trial for Elevidys
(17h)
MeiraGTx buys back gene therapy from J&J Storm brings in $56M Series C
(17h)
Blurring the lines of healthcare AI
(18h)
Using versus selling lucrative PRVs: Moderna's cautionary tale
(18h)
MSF says Gilead's lenacapavir supply 'not nearly enough'; PolyPeptide’s strategic review
(18h)
Lilly's obesity pill heads for diabetes filing after heart risk trial
(21h)
Freya Biosciences advances microbial treatment for IVF implantation failure
(1d)
BioSpace
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
(4h)
Funding the Future of European Biotech
(10h)
Trump nominates new CDC director, appoints various leaders to embattled agency
(10h)
Drug pricing watchdog calls for increased transparency into FDA’s accelerated approval decisions
(16h)
FDA mulls compounding for peptides previously flagged over safety risks
(16h)
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from JJ
(18h)
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
(18h)
Can Europe turn world-class science into world-class scale?
(18h)
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
(19h)
Revolution doubles stock offering target to $2B following pancreatic cancer win
(20h)
STAT News
Health care is not ready for the new era of AI-enabled cyberattacks
(14m)
Don’t believe headlines saying that vaccine skepticism is widespread
(14m)
HaloMD’s legal win highlights the difficulty of challenging arbitration decisions
(10h)
Trump taps former public health leader Erica Schwartz to run CDC
(12h)
A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment
(13h)
Kennedy focuses on affordability, combating fraud in Capitol Hill hearing
(14h)
Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target
(16h)
Cochrane review reignites Alzheimer’s amyloid wars
(17h)
RFK Jr. begins his testimony marathon
(18h)
We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more
(19h)
BioPharma Trend
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2d)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(1w)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(1w)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1w)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2w)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2w)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2w)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2w)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(3w)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(3w)
Drug Channels
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
(2d)
Informa Connect’s Life Sciences Pricing & Contracting USA
(4d)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(6d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(1w)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(1w)
Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
(1w)
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
(2w)
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
(2w)
European Biotechnology Magazine
Proteins.1 launches with €4.7m to make protein detection as easy as PCR
(19h)
Spain plants US$200m flag in Boston with debut US biotech fund
(1d)
Novo Nordisk is going all in on AI
(2d)
Can Europe finance and keep its biotech winners?
(2d)
Europe’s distinct biotech venture studio model
(2d)
Adcendo banks US$75m to push ADC pipeline forward
(2d)
Clean Food Group to scale yeast-based oils with £4.5m in the bank
(3d)
BioNTech reports promising Phase II data for uterine cancer ADC
(5d)
Basilea lands US$6m CARB X boost for novel antibiotic
(1w)
SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026
(1w)
Drug Hunter
BMS-986482
(18h)
FBXO22: An Emerging E3 Ligase for TPD
(1d)
BHV-2100
(2d)
orforglipron
(3d)
Module 3 Quiz
(3d)
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
(7d)
relacorilant (CORT125134)
(1w)
More Firepower Per Molecule: Bispecific and Dual-payload ADCs Push for Greater Efficacy
(1w)
TNO155
(1w)
Module 3, Section 2: Quality not Quantity
(1w)
Labiotech.EU
Argobio: the venture model building Europe’s next biotech champions
(44m)
Eight allergy companies to watch in 2026
(1d)
Mending university and venture capital relations: is it possible to see eye-to-eye?
(2d)
Can phage therapy answer the booming antibiotic resistance problem?
(2d)
Amgen pipeline’s next growth cycle: replacing its old blockbusters
(3d)
Top biotech deals in March 2026
(6d)
Multi-agent AI delivers reliable and scalable insights for single-cell omics
(1w)
Extracellular vesicles: a growing pipeline still searching for validation
(1w)
The biggest biotech funding rounds in March 2026
(1w)
The future of cell & gene therapy: Key trends to watch
(1w)
Bio IT World
SPT Labtech and EMBL GeneCore Team Up for Fully Walkaway Automated Genomics Workflows
(1d)
AWS Launches Agentic Drug Discovery-Wet Lab Pipeline
(1d)
PARTAGE Method Reveals Genome Regulation in Single Approach
(3d)
CAS Releases Agentic Tool for Literature Discovery
(1w)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(1w)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(1w)
Inductive Bio on a Winning Streak With ADMET Predictions
(2w)
From Data to Discovery: Inside the Bio-IT Hackathon
(2w)
Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
(3w)
The Value of Prediction, and Cost of Success, in Drug Hunting
(3w)
GEN News
Stem Cell Editing Programs the Immune System to Make Own Therapeutic Proteins
(7h)
Intercellular Communication via Condensate Corona-Nanoparticle Complexes
(13h)
Brain Circuits Underlying Placebo Pain Relief Identified in Mice
(14h)
Proteins.1 Launches to Develop Single Molecule Protein Amplification Tech for Diagnostics
(14h)
Advances in Stem Cell‑Derived Insulin‑Producing Cells for Type 1 Diabetes
(14h)
AACR 2026 Chairs Identify Themes and Highlights from the Conference
(16h)
Integrated Sample Preparation System Standardizes and Streamlines Pre-Analytical Workflows
(16h)
Landmark Pancreatic Cancer Trial Highlights Promise of RAS-Targeting Daraxonrasib
(18h)
Pregnancy Sickness Study Identifies New Genetic Links
(1d)
Fujifilm Biotechnologies Opens New QC Lab in Denmark
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(4w)
Understanding High-Risk Essential Thrombocythemia
(4w)
Son’s Decision to Donate Gave His Father a Second Chance
(4w)
Functional Precision Medicine Advances Brain Tumor Care
(4w)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(4w)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(4w)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(4w)
How Honest Conversations Strengthened a Couple After Cancer
(4w)
Cardiac Health in Cancer Survivors: A Growing Need
(4w)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(4w)
Contract Pharma
Mabwell Secures Strategic License and Commercialization Agreement for Denosumab Biosimilars in Malaysia
(13h)
Harbour BioMed Appoints Adam Zong, PhD, President
(15h)
BioMed X France Launches First Research Team on Servier’s R&D Campus
(16h)
Panthera Biopartners Acquires Hungarian CRO OEC
(18h)
Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy
(18h)
Piramal, Aji Bio-Pharma Partner to Support ADC Development & Manufacturing
(19h)
Helus Pharma Appoints Dr. Ken Kramer as SVP, Medical Affairs
(19h)
SQ Innovation and FIS Ink Agreement for Long-Term Supply of Pharma-Grade Furosemide
(1d)
WuXi Biologics Garners ISO 13485 Certification for Drug-Device Combination Product Manufacturing
(1d)
Curative Biotech Engages Sterling Pharma for Clinical Supply of Metformin-Based Ophthalmic Treatment
(1d)
Pharma Times
Transgene completes randomisation in phase 2 trial of tg4050
(4d)
Bayer wins MHRA approval for Kerendia in heart failure
(4d)
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(1w)
Kainova expands DT 7012 trial into Europe
(1w)
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
(1w)
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
(1w)
FDA approves new high dose Spinraza regimen for SMA
(2w)
Viridian reports positive results from elegrobart phase 3 trial
(2w)
Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
(2w)
Kygevvi approved in Europe as first treatment for TK2d
(2w)
Medcity News
Wisp, Visby Partner to Expand Access to At-Home STI Test
(11h)
CMS’ New ‘App Store’ Is Trying to Turn Interoperability Into a Digital Health Distribution System
(11h)
Startup Nula Emerges to Advance a New Class Medicines for Metabolic Disease
(13h)
The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease
(19h)
The End of Incrementalism: Why Healthcare Innovation is Finally Reshaping the Model
(19h)
New Bill Seeks to Lower Out-of-Pocket Drug Costs
(1d)
Why Innovaccer Is Pouring $250M into Its Agentic AI Platform
(1d)
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
(1d)
From Insight to Intervention: Why Over-the-Counter Digital Therapeutics (ODTx) are the Next Step for LLMs and Wearables
(1d)
The Last Mile Problem in AI Radiology: Detection Improves, Follow-Through Breaks
(1d)
Chemical & Engineering News
Iran war is benefiting some European chemical makers
(13h)
ACS Colloid and Surface Science Symposium turns 100
(15h)
Blood-brain barrier integrity depends on a glycan-cleaving enzyme
(19h)
Apollo Health Ventures launches new start-up with $20 million in federal funds
(21h)
Middle East hostilities expose a chemical-nonproliferation blind spot
(1d)
Periodic Graphics: The chemistry of smoking foods
(1d)
Restart of US small-business research grants may be too late for some
(1d)
Gregory C. Fu receives 2026 Award for Creativity in Molecular Design and Synthesis
(1d)
Comment: To caucus, or not to caucus: That is the question
(1d)
Eric Jacobsen named 2026 F. A. Cotton Medal winner
(1d)
The Pharma Letter
Ryght AI introduces world’s first, free, AI-powered clinical trial site search engine
(48m)
MeiraGTx reacquires bota-vec rights and prices public offering
(10h)
Alethio Therapeutics unveils ATX-011, a breakthrough for treating essential thrombocythemia
(17h)
ICER white paper on accelerated approval pathway for Rx drugs
(17h)
Daiichi Sankyo transfers healthcare unit to Suntory
(18h)
Mochida inks agreement for a biosimilar of follitropin alfa
(19h)
Terremoto investors see ‘full potential of selective AKT1 inhibition’
(19h)
Terremoto investors see ‘full potential of selective AKT1 inhibition’
(19h)
STORM’s $56 million Series C to power Phase II sarcoma trial
(20h)
SQ Innovation secures furosemide API supply deal
(21h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(1mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(1mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(1mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(1mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(1mo)
MedWatch
Novo Nordisk's Wegovy tablet continues to gain US market share
(11m)
Eli Lilly to submit diabetes pill for US approval this quarter
(36m)
New study: Weight-loss medication may be effective against arthritis
(56m)
His daughter's diagnosis marked the beginning of a mission: Now he has secured seed funding to see it through
(19h)
Novo Holdings invests in US biotech company
(19h)
New study casts doubt on amyloid drugs for treating Alzheimer's
(20h)
UK greenlights Wegovy for post-heart attack cardiovascular treatment
(20h)
Freya Biosciences fertility drug candidate shows promising results in first study
(21h)
MSD makes major purchases prior to patent expiry on Keytruda
(22h)
New biopharma fund aims to address Europe’s capital shortage
(23h)
In The Pipeline
Anti-Amyloid Antibodies for Alzheimer: You Already Know
(12h)
Antimalarial Drugs Stepping On Each Other's Toes
(1d)
Answers and Reasons and Knowing and Thinking
(2d)
Predicting Antibody Binding: No Champagne Just Yet
(3d)
Consider the Selfish Ribosome
(6d)
New Bond Formations Just Keep On Coming
(1w)
Ah, Peptides. Where to Begin?
(1w)
A New Opioid Agonist?
(2w)
Say "Chameleonicity" Three Times Fast. Or Read This Post.
(2w)
Right Through the Skull
(2w)
Pharmaphorum
UK says it has hit target on commercial trial set-up times
(12h)
Lift for UK healthtech as fund bags £100m from national bank
(18h)
FDA accelerated approval path needs improvement, says ICER
(19h)
Lilly says Foundayo safety confirmed in ACHIEVE-4 trial
(20h)
Beeline raises $300m for BMS drugs, and other biofinancings
(21h)
Most patients "won't see benefit" with Alzheimer's drugs
(22h)
Novartis CEO joins board of "responsible" AI firm Anthropic
(1d)
Scientists issue call to arms over antifungal resistance
(1d)
Daiichi exits OTC, with $1.55bn unit sale to Suntory
(1d)
Parkinson's charity partners Biognosys on biomarker project
(1d)
Drug Discovery Weekly
Supercomputing collaboration to advance dermatology research
(44m)
Asgard Therapeutics appoints Dr Wolfram Brugger as CMO
(17h)
Novel therapy could slow tumour growth, results find
(19h)
Regulatory reforms accelerate UK clinical trial set up
(21h)
Advanced Therapies London 2026: Moving from ambition to application
(23h)
Speech overlooked as clinical marker, biotech says
(23h)
Webinar: Learn how to streamline ADC discovery
(1d)
Research collaboration to ‘strengthen pandemic preparedness’
(1d)
Construction completed on new UK life science facility
(1d)
Access to hyperkalaemia drug expands across England and Wales
(2d)
HIT Consultant
Automating Behavioral Health Utilization Review to Reduce Denials
(1h)
Why AMA Data Shows Physician Burnout is No Longer a ‘One-Size-Fits-All’ Crisis
(11h)
Keebler Health Secures $16M to Scale LLM-Native Risk Adjustment Platform
(12h)
Carrot Launches ‘Carrot Intelligence’ AI Platform for Global Fertility and Family Care
(17h)
Worki Raises $2.75M to Build the AI Infrastructure for the Healthcare Workforce
(18h)
ARC Launches ‘ARC Landing Boston’ Healthtech Accelerator with Massachusetts Governor Maura Healey
(18h)
Walmart Expands Better Care Services Platform with GLP-1 Weight Management Offerings
(18h)
Wegovy HD Now Available on GoodRx for $399 Per Month Self-Pay
(19h)
M&A: D2 Solutions Acquires ProModRx to Streamline Patient Journeys
(19h)
Why Hospital Dashboards Tell the Future But Operations Remain Stuck in the Past
(1d)
Insights: Pink Sheet
Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals
(3h)
Japan Pricing Roundup: Rapid Idvynso Reimbursement, CEA Cut For Briviact
(8h)
US FDA’s Principal Deputy Commissioner Moving To HHS As Senior Counselor For Public Health
(10h)
Relief For ‘Low T’? US FDA Eyes Literature-Based Expansion For Testosterone Therapy
(10h)
RFK Jr. Defends Makary’s US FDA Record, Refutes Claims Of Chilled Biopharma Investment
(11h)
Buying Time: How Much Is Lilly’s Foundayo CNPV Worth?
(15h)
Saudi FDA Offers Priority Review, Rolling Submissions For Novel Therapies
(19h)
EMA To Update Decade-Old Guidance On ALS Trials Amid Ongoing Unmet Need
(20h)
Optic Neuritis Drug Among Three Promising Treatments To Secure EMA PRIME Designations
(20h)
Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks
(1d)
BioXconomy
Storm Therapeutics strikes sarcomas with $56m Series C thunder
(17m)
Compliance updates—OPDP, EU regulatory, CSRD and 340B
(11h)
Avanos Medical to begin a new chapter: Acquired by AIP in $1.27bn deal
(16h)
Beyond Redaction: Governing Confidential Information in an Era of Expaning Transparency
(18h)
AbbVie eases the pain with $745m licensing deal
(21h)
Reverse mergers in biotech: A strategic path to public markets
(23h)
FDA proposes faster Phase I trial approvals to boost US competitiveness
(1d)
Redefining trust: AI’s impact on clinical research
(1d)
Allucent restructures leadership team to strengthen biopharma support
(1d)
Eli Lilly bets $300m on CrossBridge Bio's dual-payload ADC platform
(1d)
BioCentury
Autoimmune T cell engagers diverge from their oncology roots
(8h)
Scala Biodesign: embedding biologic design into pharma R&D workflows
(9h)
Now in clinic, Neomorph heads into AACR with $100M series B: Venture Report
(10h)
FDA’s peptide plans reinforce concerns about ideology, politics influencing its decisions
(1d)
Structure hires Metsera alum Lang as COO, general counsel
(1d)
A 32-year look at biotech’s capital expansion
(1d)
U.S. still top spot for Phase I trials, but China leads in I&I, metabolic disease
(1d)
Remembering Sofinnova’s Denis Lucquin, father of French biotech
(2d)
Novartis’ Narasimhan joins Anthropic board
(2d)
Zentalis leads movers in trio of ovarian cancer updates
(2d)
SCRIP
Japan Q1 Roundup Podcast: Iran War Impact, Divestments, Product Approvals
(5h)
Lilly To Head To FDA After Demonstrating Foundayo’s Cardiovascular, Liver Safety
(12h)
Storm Raises $56m To Take RNA Modification Inhibitor Into Phase II
(16h)
Diamyd Down In The Dumps After Diabetes Drug Fail
(19h)
Executives On The Move: Ailux Gets A New CSO From AstraZeneca
(19h)
Pharma Gains A Seat At The AI Table As Anthropic Taps Novartis’s Narasimhan
(19h)
D&D Pharmatech Raises $154m To Progress MASH, Core Assets
(1d)
Prolonged US Blockade Of Iran Ports Risks Drug Shortages, Wider Supply Chain Woes
(1d)
Jazz Talks Deals Amid Business Strategy Evolution
(1d)
Revolution’s Strong Data Garner An Upsized Investor Response
(1d)